Quidel immunoassay system receives CE Mark
On receiving CE Mark, Quidel now plans to launch the product in Europe. The product has already carved a place in some parts of the world market, including
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).